Association of NAD+ levels with metabolic disease in a community-based study

Background Nicotinamide adenine dinucleotide (NAD+) is a coenzyme and plays a crucial role in several metabolic processes. This study explored the association of nicotinamide adenine dinucleotide (NAD+) levels with metabolic disease (MD) in adults. Methods In this cross-sectional study, all data were collected from the Jidong community. MD was defined as the presence of one or more of the following disease components: hypertension, dyslipidemia, diabetes, hyperuricemia, obesity, and non-alcoholic fatty liver disease (NAFLD). The MD components were categorized into three groups: those with one component, those with two components, and those with three to six components. The whole blood NAD+ level was measured using a cycling assay and LC-MS/MS analysis. The participants were divided into four groups based on their NAD+ level quartiles. Multivariable logistic regression was used to evaluate the association of the whole blood NAD+ levels with MD. Results Of the 1,394 eligible participants, the average age was 43.2 years, and 74.3% had MD. In the top quartile of NAD+, the prevalence of MD and each of its components (hypertension, hyperlipidemia, diabetes, hyperuricemia, obesity, and NAFLD) were 87.9% 35.2%, 62.3%, 8.7%, 36.9%, 21.0%, and 60.5%, respectively. As compared with the lowest NAD+ quartile (≤29.4 μmol/L), the adjusted odds ratios and 95% confidence interval of the highest quartile were 3.01 (1.87-4.87) for MD, 2.48 (1.44-4.29) for 1 MD component, 2.74 (1.45-5.17) for 2 MD components, and 4.30 (2.32-7.98) for 3-6 MD components. The risk of MD began to increase at NAD+ levels of 31.0 μmol/L, as revealed by the gradient associations of NAD+ levels with MD. There was no significant interaction between age, sex, drinking, smoking, and NAD+ for MD (p for interaction ≥0.10). Conclusions Increased NAD+ was significantly associated with MD, as well as its individual components. Our findings provide new evidence for the relationship between blood NAD+ levels and MD.

[1]  I. Milisav,et al.  The Central Role of the NAD+ Molecule in the Development of Aging and the Prevention of Chronic Age-Related Diseases: Strategies for NAD+ Modulation , 2023, International journal of molecular sciences.

[2]  Z. Ju,et al.  Association of Human Whole Blood NAD+ Contents With Aging , 2022, Frontiers in Endocrinology.

[3]  Juan Xiao,et al.  Associations Between Abdominal Obesity Indices and Nonalcoholic Fatty Liver Disease: Chinese Visceral Adiposity Index , 2022, Frontiers in Endocrinology.

[4]  M. Cushman,et al.  Pro-Neurotensin/Neuromedin N and Risk of Incident Metabolic Syndrome and Diabetes Mellitus in the REGARDS Cohort. , 2021, The Journal of clinical endocrinology and metabolism.

[5]  T. Haregu,et al.  The Prevalence of Metabolic Disease Multimorbidity and Its Associations With Spending and Health Outcomes in Middle-Aged and Elderly Chinese Adults , 2021, Frontiers in Public Health.

[6]  J. Baur,et al.  Role of NAD+ in regulating cellular and metabolic signaling pathways , 2021, Molecular metabolism.

[7]  R. Pranata,et al.  BMI and atrial fibrillation recurrence post catheter ablation: A dose‐response meta‐analysis , 2021, European journal of clinical investigation.

[8]  G. Ptak,et al.  The effects of assisted reproduction technologies on metabolic health and disease† , 2020, Biology of reproduction.

[9]  V. Howard,et al.  Pro-neurotensin/neuromedin N and risk of ischemic stroke: The REasons for Geographic And Racial Differences in Stroke (REGARDS) study , 2020, Vascular medicine.

[10]  J. Manly,et al.  Pro-Neurotensin/Neuromedin N and Risk of Cognitive Impairment in a Prospective Study. , 2020, Journal of Alzheimer's disease : JAD.

[11]  L. Quek,et al.  EXERCISE-INDUCED BENEFITS ON GLUCOSE HANDLING IN A MODEL OF DIET-INDUCED OBESITY ARE REDUCED BY CONCURRENT NICOTINAMIDE MONONUCLEOTIDE , 2020, bioRxiv.

[12]  Hao Li,et al.  Associations of Aminotransferases with Adverse Outcomes after Acute Ischemic Stroke: Results from China National Stroke Registry , 2020 .

[13]  H. Tilg,et al.  The intestinal microbiota fuelling metabolic inflammation , 2019, Nature Reviews Immunology.

[14]  D. Sinclair,et al.  Sirtuins and NAD+ in the Development and Treatment of Metabolic and Cardiovascular Diseases , 2018, Circulation research.

[15]  J. Reid,et al.  Two Different Methods of Quantification of Oxidized Nicotinamide Adenine Dinucleotide (NAD+) and Reduced Nicotinamide Adenine Dinucleotide (NADH) Intracellular Levels: Enzymatic Coupled Cycling Assay and Ultra-performance Liquid Chromatography (UPLC)-Mass Spectrometry. , 2018, Bio-protocol.

[16]  O. Melander,et al.  Proneurotensin Predicts Cardiovascular Disease in an Elderly Population , 2018, The Journal of clinical endocrinology and metabolism.

[17]  J. Park,et al.  PD13-10 IMPACT OF METFORMIN ON SERUM PROSTATE-SPECIFIC ANTIGEN LEVELS: DATA FROM THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY 2007-2008 , 2018 .

[18]  J. Loscalzo,et al.  NAD(H) and NADP(H) Redox Couples and Cellular Energy Metabolism. , 2018, Antioxidants & redox signaling.

[19]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[20]  N. Turner,et al.  NAD+: A key metabolic regulator with great therapeutic potential , 2017, Journal of neuroendocrinology.

[21]  Jens Nielsen,et al.  Personal model‐assisted identification of NAD+ and glutathione metabolism as intervention target in NAFLD , 2017, Molecular systems biology.

[22]  R. D'Agostino,et al.  Circulating Proneurotensin Concentrations and Cardiovascular Disease Events in the Community: The Framingham Heart Study , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[23]  S. French.  Chronic alcohol binging injures the liver and other organs by reducing NAD⁺ levels required for sirtuin's deacetylase activity. , 2016, Experimental and molecular pathology.

[24]  J. Kanu,et al.  Prevalence of metabolic syndrome in mainland china: a meta-analysis of published studies , 2016, BMC Public Health.

[25]  Ashutosh Kumar Singh,et al.  Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, Lancet.

[26]  E. Verdin.  NAD+ in aging, metabolism, and neurodegeneration , 2015, Science.

[27]  R. Kelishadi,et al.  Prevalence of Metabolic Syndrome and Its Components in the Iranian Adult Population: A Systematic Review and Meta-Analysis , 2015, Iranian Red Crescent medical journal.

[28]  Qingcheng Yang,et al.  Serum N(1)-Methylnicotinamide Is Associated With Obesity and Diabetes in Chinese. , 2015, The Journal of clinical endocrinology and metabolism.

[29]  R. Wong,et al.  Prevalence of the metabolic syndrome in the United States, 2003-2012. , 2015, JAMA.

[30]  Jing-quan Zhong,et al.  Association between serum uric acid and mortality in a Chinese population of hypertensive patients , 2015, Renal failure.

[31]  Yilong Wang,et al.  Association between estimated glomerular filtration rate and clinical outcomes in patients with acute ischaemic stroke: results from China National Stroke Registry. , 2014, Age and ageing.

[32]  Yilong Wang,et al.  Associations Between Estimated Glomerular Filtration Rate and Stroke Outcomes in Diabetic Versus Nondiabetic Patients , 2014, Stroke.

[33]  Bohu,et al.  Associations Between Estimated Glomerular Filtration Rate and Stroke Outcomes in Diabetic Versus Nondiabetic Patients , 2014 .

[34]  De-Pei Liu,et al.  Overexpression of SIRT1 in vascular smooth muscle cells attenuates angiotensin II-induced vascular remodeling and hypertension in mice , 2014, Journal of Molecular Medicine.

[35]  A. Kaya,et al.  Metabolic syndrome prevalence according to ATP III and IDF criteria and related factors in Turkish adults , 2013, Archives of medical science : AMS.

[36]  P. Almgren,et al.  Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality. , 2012, JAMA.

[37]  S. Imai,et al.  Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. , 2011, Cell metabolism.

[38]  Hyon K. Choi,et al.  Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. , 2011, Arthritis and rheumatism.

[39]  W. Brown.  Framingham Heart Study. , 2011, Journal of clinical lipidology.

[40]  K. Birkeland,et al.  Intracellular nicotinamide phosphoribosyltransferase protects against hepatocyte apoptosis and is down-regulated in nonalcoholic fatty liver disease. , 2010, The Journal of clinical endocrinology and metabolism.

[41]  Wieland Kiess,et al.  Nampt: linking NAD biology, metabolism and cancer , 2009, Trends in Endocrinology & Metabolism.

[42]  H. Randeva,et al.  Nuclear Factor-κB Induction by Visfatin in Human Vascular Endothelial Cells , 2008, Diabetes Care.

[43]  W. Longstreth,et al.  The REasons for Geographic And Racial Differences in Stroke (REGARDS) Study and the National Institute of Neurological Disorders and Stroke (NINDS). , 2006, Stroke.

[44]  H. G. Goovaerts,et al.  A Meta‐analysis of Published Studies Concerning the Validity of Thoracic Impedance Cardiography , 1999, Annals of the New York Academy of Sciences.